Literature DB >> 32426098

Feasibility of robotic assisted bladder sparing pelvic exenteration for locally advanced rectal cancer: A single institution case series.

Nathaniel H Heah1, Kar Yong Wong2.   

Abstract

BACKGROUND: Pelvic exenteration for locally advanced rectal cancer involving prostate has been performed via open surgery. Robotic pelvic exenteration offers benefits of better pelvic visualisation and dissection for bladder preserving prostatectomy with vesicourethral anastomosis, while achieving clear margins. AIM: To determine the feasibility of robotic assisted bladder sparing pelvic exenteration.
METHODS: We describe robotic assisted pelvic exenteration in three cases of locally advanced rectal cancer involving prostate and seminal vesicles (SV). The da Vinci S robotic system was used. Robotic console was docked at left oblique position for abdominal phase and redocked to between the patient's legs for pelvic phase. All three cases were performed fully robotically at Tan Tock Seng Hospital by colorectal and urological teams.
RESULTS: Case 1: 67-year-old with low rectal tumour 3cm from anal verge involving the prostate. He underwent neo-adjuvant chemoradiotherapy and robotic abdominoperineal resection with en-bloc prostatectomy. Case 2: 66-year-old with low rectal tumour 3cm from anal verge involving prostate and bilateral SV. He underwent neo-adjuvant chemoradiotherapy and robot assisted ultra-low anterior resection with coloanal anastomosis and en-bloc prostatectomy. Case 3: 57-year-old with metachronous rectal tumour in the rectovesical pouch inseparable from the anterior mid rectum, prostate and bilateral SV. He underwent robot assisted ultra-low anterior resection with en-bloc prostatectomy. Bladder neck margin revealed cauterized tumour cells, and he underwent total cystectomy and ileal conduit creation. Histology revealed no residual tumour. All patients are currently disease free.
CONCLUSION: Robot assisted bladder sparing pelvic exenteration can be safely performed in locally advanced rectal cancer with acceptable surgical outcome while preserving benefits of minimally invasive surgery. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Anterior resection; Minimal invasive surgery; Pelvic exenteration; Prostatectomy; Rectal cancer; Robot surgery

Year:  2020        PMID: 32426098      PMCID: PMC7215973          DOI: 10.4240/wjgs.v12.i4.190

Source DB:  PubMed          Journal:  World J Gastrointest Surg


  10 in total

Review 1.  Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome.

Authors:  S Trastulli; E Farinella; R Cirocchi; D Cavaliere; N Avenia; F Sciannameo; N Gullà; G Noya; C Boselli
Journal:  Colorectal Dis       Date:  2012-04       Impact factor: 3.788

2.  Robotic-assisted multivisceral resection for rectal cancer: short-term outcomes at a single center.

Authors:  H Hino; T Yamaguchi; Y Kinugasa; A Shiomi; H Kagawa; Y Yamakawa; M Numata; A Furutani; Y Yamaoka; S Manabe; T Suzuki; S Kato
Journal:  Tech Coloproctol       Date:  2017-11-13       Impact factor: 3.781

3.  Robotic total pelvic exenteration.

Authors:  Akhil Lawande; Rahul Kenawadekar; Riddhi Desai; Chaitanya Malireddy; Kathya Nallapothula; Shailesh P Puntambekar
Journal:  J Robot Surg       Date:  2013-05-05

4.  Robotic assisted minimally invasive pelvic exenteration in advanced rectal cancer: review and case report.

Authors:  P R Nanayakkara; S A Ahmed; D Oudit; S T O'Dwyer; C R Selvasekar
Journal:  J Robot Surg       Date:  2013-06-01

5.  First report: Robotic pelvic exenteration for locally advanced rectal cancer.

Authors:  J W Shin; J Kim; J M Kwak; M Hara; J Cheon; S H Kang; S G Kang; A R L Stevenson; G Coughlin; S H Kim
Journal:  Colorectal Dis       Date:  2014-01       Impact factor: 3.788

6.  Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.

Authors: 
Journal:  Br J Surg       Date:  2013-07       Impact factor: 6.939

Review 7.  A Systematic Review to Assess Resection Margin Status After Abdominoperineal Excision and Pelvic Exenteration for Rectal Cancer.

Authors:  Constantinos Simillis; Daniel L H Baird; Christos Kontovounisios; Nikhil Pawa; Gina Brown; Shahnawaz Rasheed; Paris P Tekkis
Journal:  Ann Surg       Date:  2017-02       Impact factor: 12.969

8.  Abdominoperineal excision with partial anterior en bloc resection in multimodal management of low rectal cancer: a strategy to reduce local recurrence.

Authors:  Kennet Smedh; Maziar Hosseinali Khani; Wolfgang Kraaz; Yngve Raab; Eva Strand
Journal:  Dis Colon Rectum       Date:  2006-06       Impact factor: 4.585

9.  Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy?

Authors:  H Patel; J V Joseph; A Amodeo; K Kothari
Journal:  J Minim Access Surg       Date:  2009-10       Impact factor: 1.407

10.  Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base.

Authors:  Helmneh M Sineshaw; Ahmedin Jemal; Charles R Thomas; Timur Mitin
Journal:  Cancer       Date:  2016-04-13       Impact factor: 6.860

  10 in total
  3 in total

1.  Robot-assisted total pelvic exenteration for rectal cancer after neoadjuvant chemoradiotherapy: a case report.

Authors:  Kyoichi Kihara; Yuri Koyama; Takehiko Hanaki; Kozo Miyatani; Tomoyuki Matsunaga; Manabu Yamamoto; Shuichi Morizane; Naruo Tokuyasu; Teruhisa Sakamoto; Yoshiyuki Fujiwara
Journal:  Surg Case Rep       Date:  2022-10-07

Review 2.  Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.

Authors: 
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.575

Review 3.  Robotic Surgery in Rectal Cancer: Potential, Challenges, and Opportunities.

Authors:  Ge Liu; Shoujia Zhang; Yan Zhang; Xiaoqing Fu; Xinlu Liu
Journal:  Curr Treat Options Oncol       Date:  2022-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.